Model-Based Nanoengineered Pharmacokinetics of Iron-Doped Copper Oxide Applicable to Nanomedicine.
The progress in nanomedicine (NM) using nanoparticles (NPs) is mainly based on drug carriers for the delivery of classical chemotherapeutics. While low NM delivery rates limit therapeutic efficacy, an entirely different approach was investigated. A homologous series of engineered CuO NPs was designed for dual purpose (carrier and drug) with a direct chemical composition-biological functionality relationship. Model-based dissolution kinetics (initial burst-like followed by a solid state diffusion limited long-term release) of CuO NPs in the cellular interior at post exposure conditions were controlled via for intra/extra cellular Cu 2+ for biological outcome. Through controlled ion release and reactions taking place in the cellular interior, tumors could be treated selectively, in vitro and in vivo . Locally administered NMs enabled tumor cells apoptosis and stimulated systemic anti-cancer immune responses. In this work we clearly show therapeutic effects without tumors cells relapse post treatment with 6% Fe-doped CuO NPs combined with myeloid-derived suppressor cell (MDSC) silencing.